Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biogen Inc. (BIIB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. As a Nasdaq-listed biotechnology company, Biogen uses these filings to report financial results, material events and governance matters that are important for investors evaluating its activities in neurology, rare diseases and immunology.
Recent Form 8-K filings show how Biogen communicates results of operations and financial condition, including quarterly earnings press releases and preliminary estimates of acquired in-process research and development, upfront and milestone expenses. The company explains that these expenses arise from collaboration and license agreements and are presented as a separate line item in its condensed consolidated statements of income. Other 8-K filings cover shareholder votes at the annual meeting, such as the election of directors and ratification of the independent registered public accounting firm.
Through this page, users can review Biogen’s SEC-reported information alongside Stock Titan’s AI-powered tools, which can help summarize lengthy filings and highlight key items such as collaboration-related charges, capital allocation decisions and governance outcomes. Investors interested in Biogen’s partnerships, pipeline investments and financial reporting practices can use these filings to understand how the company accounts for its research collaborations, including those involving antisense oligonucleotides, monoclonal antibodies and emerging modalities.
In addition to 8-Ks, this page can link to other Biogen filings available on EDGAR, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company provides more detailed discussion of its business, risk factors and financial statements. Together, these documents form the regulatory record that underpins fundamental analysis of BIIB.
Biogen Inc. executive Ginger Gregory, EVP of Human Resources, reported multiple equity award transactions dated 02/06/2026. The filing shows restricted stock units converting into common stock at an exercise price of $0 and related dispositions of common shares at $201.18 per share.
Individual conversions include 1,635, 1,802, and 3,746 restricted stock units, each linked to previously granted awards scheduled to vest in three equal annual installments beginning one year after their respective grant dates in 2023, 2024, and 2025. Following these transactions, Gregory directly holds 22,358.7673 shares of Biogen common stock and 7,494 restricted stock units.
Biogen Inc. (BIIB) Chief Accounting Officer Sean Godbout reported multiple equity compensation transactions dated February 6, 2026. Restricted stock units for 257, 305, and 517 shares were converted (code M) into common stock at an exercise price of $0 per share.
On the same date, he disposed of 76, 103, and 180 common shares (code F) at $201.18 per share. Following these transactions, Godbout directly owned 1,214.6667 shares of Biogen common stock.
Biogen Inc. executive Susan H. Alexander, EVP Chief Legal Officer, reported multiple equity transactions on 02/06/2026. Several restricted stock unit awards were exercised, delivering 2,190, 1,940 and 4,916 shares of Biogen common stock at an exercise price of $0.
In related transactions, 1,059, 931 and 1,514 shares of common stock were withheld at a price of $201.18 per share, typically reflecting shares retained to cover tax obligations. After these transactions, she directly held 41,807 shares of Biogen common stock and indirectly held 20,082 shares through the Susan H. Alexander 2021 Irrevocable Trust.
Biogen insider Priya Singhal has filed a notice to sell company stock. The filing covers a proposed sale of 2,660 shares of Biogen common stock through Fidelity Brokerage Services LLC on 02/09/2026, listed on NASDAQ, with an aggregate market value of 531,547.80.
The shares to be sold come from recent restricted stock vesting awards. She acquired 1,963 shares on 02/06/2026 and 697 shares on 02/07/2026, both described as compensation from the issuer. In the past three months, she also sold 748 common shares on 02/02/2026 for gross proceeds of 134,116.40.
Biogen Inc. describes its 2025 business, strategy and major pipeline moves in neurology, specialized immunology and rare diseases. The company markets MS drugs such as VUMERITY and TYSABRI, SPINRAZA for SMA, SKYCLARYS for Friedreich ataxia, QALSODY for SOD1 ALS, LEQEMBI for early Alzheimer’s disease and ZURZUVAE for postpartum depression, alongside multiple biosimilars and anti‑CD20 revenue-sharing products with Genentech.
Key 2025 actions include acquiring Alcyone Therapeutics for about $85 million to control ThecaFlex DRx delivery technology, entering new collaborations with Dayra, Vanqua, City Therapeutics and Stoke with upfront payments ranging from $16 million to $165 million, and securing up to $250 million in litifilimab co-funding via a $200 million Royalty Pharma development financing recorded as an R&D offset. Biogen also issued $1.75 billion of 2025 senior notes, signed a 15.5‑year lease for a 580,000‑square‑foot Cambridge headquarters to support a planned 40% Massachusetts footprint reduction, advanced multiple Phase 3 programs (including felzartamab, salanersen and zorevunersen) and recorded numerous global label and access expansions for LEQEMBI, SPINRAZA, SKYCLARYS and QALSODY.
Biogen Inc. reported mixed fourth quarter and full year 2025 results and issued 2026 guidance. Full year 2025 total revenue was $9.9 billion, up 2% from 2024, with GAAP diluted EPS of $8.79 and Non-GAAP diluted EPS of $15.28, above the prior guidance range of $14.50–$15.00. Q4 2025 revenue was $2.28 billion, down 7% year over year, with a GAAP diluted loss per share of $(0.33) and Non-GAAP diluted EPS of $1.99.
Growth products were a key driver: 2025 revenue from these medicines rose 19% year over year, offsetting declines in multiple sclerosis products (excluding VUMERITY). LEQEMBI generated about $134 million of Q4 global in‑market sales, up 54% year over year, while SKYCLARYS and ZURZUVAE also showed strong demand. Multiple sclerosis product revenue fell 7% for the year, rare disease revenue grew 8%, and biosimilars revenue declined 8%.
For 2026, Biogen expects Non-GAAP diluted EPS between $15.25 and $16.25 and total revenue to decline by a mid‑single‑digit percentage versus 2025, with gross margin and combined Non‑GAAP R&D and SG&A expenses roughly consistent year over year. The company highlighted late‑stage pipeline momentum, including FDA Priority Review for LEQEMBI IQLIK initiation and Breakthrough Therapy Designation for litifilimab in cutaneous lupus, with multiple Phase 3 readouts anticipated through 2029.
FMR LLC and Abigail P. Johnson report significant ownership of Biogen Inc.12/31/2025, they beneficially owned 9,413,062.03 shares, representing 6.4% of the class.
FMR LLC held sole voting power over 8,291,794.64 shares and sole dispositive power over 9,413,062.03 shares
Biogen Inc.’s Head of Development, Priya Singhal, reported equity transactions involving company stock. On January 30, 2026, 1,829 shares of common stock were acquired at $0 following the vesting and exercise of a restricted stock unit award granted on February 1, 2023 that vests in three equal annual installments.
Also on January 30, 2026, 582 shares were surrendered at $179.89, and on February 2, 2026, 748 shares were sold at $179.3. After these transactions, Singhal directly held 6,271.1428 shares of Biogen common stock.
A holder of 748 shares of common stock of a NASDAQ-listed company has filed a notice of proposed sale under Rule 144. The shares have an aggregate market value of 134116.40 and are planned to be sold on 02/02/2026 through Fidelity Brokerage Services LLC on NASDAQ.
The securities were recently acquired on 02/01/2026 via restricted stock vesting from the issuer as compensation. The filer represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Biogen Inc. is signaling a sizeable one-time expense in its upcoming fourth-quarter 2025 results. The company expects to record approximately $222 million of acquired in-process research and development, upfront and milestone expense on a pre-tax basis, which it estimates will reduce GAAP and non-GAAP net income per diluted share for the quarter by about $1.26.
This line item reflects costs tied to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions. Biogen began presenting this expense as a separate line item in its income statement in the first quarter of 2025 and notes that it does not forecast such costs because their timing and size are inherently uncertain. The company also emphasizes that its results for the quarter ended December 31, 2025 are preliminary and may change as normal closing procedures are completed.